Novo Nordisk raised full-year guidance on stronger-than-expected uptake of its Wegovy pill, while GSK secured a $1 billion siRNA deal with China’s SiranBio targeting cardiometabolic disease. Bayer announced its largest acquisition in years, agreeing to buy Perfuse Therapeutics for up to $2.45 billion to bolster its eye drug pipeline, and Avalo Therapeutics posted positive Phase 2 data in inflammatory skin disease while raising $375 million to advance development.
What to Watch
- Oral GLP-1 trajectory — Novo’s raised guidance suggests the Wegovy pill is capturing share faster than anticipated; competitive response from Lilly and emerging players will determine whether oral formulations expand or cannibalize the injectable obesity market.
- China biotech partnerships — GSK’s SiranBio deal follows a pattern of Western pharma licensing early-stage innovation from Chinese startups; watch for geopolitical or regulatory friction as these agreements proliferate.
- Epigenetic oncology — CellCentric’s $220M raise for p300/CBP inhibition in myeloma reflects renewed interest in chromatin modulators; pivotal data could reopen investor enthusiasm for epigenetic targets beyond HDACs and EZH2.
- mRNA delivery innovation — ParcelBio’s claim to solve a core delivery problem warrants scrutiny; if validated, could unlock extrahepatic mRNA applications in CNS, lung, and muscle tissue.
